Orchestra BioMed Announces AVIM Therapy to Be Featured in Two Sessions at HRX Live 2026
Orchestra BioMed's investigational AVIM Therapy will be featured in two sessions at HRX Live 2026, the Heart Rhythm Society's innovation-focused meeting running September 18-20, 2026 in Atlanta. A sponsored roundtable on September 19 spotlights the company's strategic collaboration with Medtronic to develop and commercialize AVIM Therapy for uncontrolled hypertension in pacemaker-indicated patients; a second panel explores pacing beyond bradycardia. Dr. Vivek Reddy, moderating the roundtable, said the BACKBEAT global pivotal trial is nearing enrollment completion, a soft milestone for the program's timeline.
Key figures
- Backbeat trial status
- nearing enrollment completion
- Fda breakthrough designations avim
- 2
- Moderato ii 24h asbp reduction mmhg
- 8.1
- Moderato ii office sbp reduction mmhg
- 12.3
- Us patients uncontrolled hypertension
- 7.7 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.